¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Beta adrenergic blocking agents"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® beta human chorionic gonadotropin ÇÑ±Û º£Å¸ »ç¶÷À¶¸ð¼º »ý½Ä»ùÀÚ±ØÈ£¸£¸ó
¼³¸í   
  Å¹ݼ¼Æ÷¿¡¼­ ¸¸µé¾îÁö´Â È£¸£¸ó. ±â´ÉÀº ÀÓ½ÅÀÇ Ãʱ⿡ È²Ã¼(¿ø·¡ ³­ÀÚ¸¦ ½Î°í ÀÖ´ø ¼¼Æ÷µéÀÌ ¹è¶õÀÌ ÀϾ¼­ ³­ÀÚ°¡ ºüÁ®³ª°£ ÈÄ ÁÖ¸Ó´Ï ¸ð¾çÀ» ÀÌ·é °Í. ÀÓ½ÅÃʱ⿡ ÀÓ½ÅÀÇ À¯Áö¿¡ ÇÊ¿äÇѠȣ¸£¸óÀ» »ý¼ºÇÑ´Ù)ÀÇ À¯Áö¿¡ ±â¿©Çϰí, Å¾ÆÀÇ °íȯÁ¶Á÷¿¡¼­ ³²¼ºÈ£¸£¸óÀÌ ºÐºñµÇ´Â °ÍÀ» ÃËÁø½ÃŲ´Ù. ¶Ç À̰ÍÀº ÀÓ½ÅÃʱâÀÇ ÀÓ»êºÎÀÇ ¼Òº¯¿¡¼­ ¸¹Àº ¾çÀÌ °ËÃâµÇ¹Ç·Î À̰ÍÀ» ÀÌ¿ëÇØ¼­ ÀÓ½ÅÀÇ ¿©ºÎ¸¦ ¼Õ½±°Ô Á¶»çÇÒ ¼ö°¡ ÀÖ´Ù.
¿µ¹® beta ray ÇÑ±Û º£Å¸¼±
¼³¸í   
  ¹æ»ç¼º ¿øÀÚÇÙÀÌ ¥âºØ±«ÇÔ¿¡ µû¶ó ¹æÃâµÇ´Â ¹æ»ç¼±. ¿øÀÚ¿¡ Á¤»óº¸´Ù ¸¹°Å³ª ÀûÀº Áß¼ºÀÚ³ª ¾çÀÚ¸¦ °¡Áö°í Àִ °æ¿ì¿¡´Â ¿øÀÚ°¡ ¾ÈÁ¤µÇ±â À§ÇÏ¿© ºØ±«°¡ ¼¼°¡Áö ¹æ¹ýÀ¸·Î »ý±ä´Ù. ÀÌÁß Áß¼ºÀÚ°¡ ÇϳªÀÇ ÀüÀÚ¸¦ ³»°í ¾ç¼ºÀÚ°¡ µÇ´Â º¯È­¸¦ °ÅÄ¡¸é¼­ ³ª¿À´Â ÀüÀÚ¼±ÀÌ´Ù. ±× ½Çü´Â °í¼ÓÀÇ ÀüÀÚ ¶Ç´Â ¾çÀüÀÚÀ̸ç ÃÖ´ë ¿¡³ÊÁö´Â 105-107eV. Åõ°ú·Â ¹× ÀÌ¿ÂÈ­ ÀÛ¿ëÀº ¥á¼±°ú ¥ã¼±ÀÇ Áß°£ Á¤µµÀÌ´Ù.
¿µ¹® beta-blocker ÇÑ±Û º£Å¸Â÷´ÜÁ¦
¼³¸í   
  º£Å¸-¼ö¿ëü(1°ú 2¿¡ °ü°è¾øÀÌ)ÀÇ ±â´ÉÀ» ¾ïÁ¦½Ã۴ ¾à¹°·Î ÀÌ ¼ö¿ëü°¡ ¸Å°³ÇÏ¿© »ý±â´Â ½ÅüÀÇ º¯È­¸¦ ¾ïÁ¦ÇÑ´Ù. PropranololÀÌ ÁÁÀº ¿¹ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼ö¿ëüÀλêÈ­È¿¼Ò
  • autonomic blocking agent
    ÀÚÀ²½Å°æÂ÷´ÜÁ¦
  • adrenergic
    1. ¾Æµå·¹³¯¸°- 2. ¾Æµå·¹³¯¸°¼º¾à
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°´ëÇ×Á¦, ¾Æµå·¹³¯¸°±æÇ×Á¦
  • adrenergic blocker
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • adrenergic drug
    ¾Æµå·¹³¯¸°ÀÛ¿ë¾à
  • adrenergic fiber
    ¾Æµå·¹³¯¸°¼¶À¯
  • adrenergic receptor
    ¾Æµå·¹³¯¸°¼ö¿ëü
  • blocking agent
    Â÷´ÜÁ¦
  • blocking antibody
    Â÷´ÜÇ×ü
  • blocking of thought
    »ç°íµÎÀý
  • cholinergic blocking agent
    Äݸ°Â÷´ÜÁ¦
  • ganglionic blocking agent
    ½Å°æÀýÂ÷´ÜÁ¦
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blocking agent
    Â÷´ÜÁ¦
  • blocking antibody
    Â÷´ÜÇ×ü
  • blocking of thought
    »ç°íµÎÀý
  • beta-carotene
    º£Å¸Ä«·Îƾ
  • beta cell
    º£Å¸¼¼Æ÷
  • beta hemolysis
    º£Å¸¿ëÇ÷
  • beta ray
    º£Å¸¼±
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼º¼ö¿ëüÀλêÈ­È¿¼Ò
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • adrenergic
    ¾Æµå·¹³¯¸°¼º¾à, ¾Æµå·¹³¯¸°-
  • adrenergic blocker
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • adrenergic drug
    ¾Æµå·¹³¯¸°ÀÛ¿ë¾à
  • adrenergic fiber
    ¾Æµå·¹³¯¸°¼¶À¯
  • adrenergic receptor
    ¾Æµå·¹³¯¸°¼ö¿ëü
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°´ëÇ×Á¦
  • beta cell
    º£Å¸¼¼Æ÷
  • beta counting
    º£Å¸°è¼ö
  • beta emitter
    º£Å¸¹æÃâ±â
  • beta error
    Á¦ÀÌÁ¾¿À·ù
  • beta hemolysis
    º£Å¸¿ëÇ÷, ¿ÏÀü¿ëÇ÷
  • beta particle
    º£Å¸ÀÔÀÚ
  • beta ray
    º£Å¸¼±
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • H2 recepor blocking agents, for ulcers
    H2¼ö¿ëüÂ÷´ÜÁ¦(â¥é»ô÷ó´Ó¨ð¥)
  • Chemosensitizing agents
    È­ÇÐÀû °¨°¢Á¦
  • health care agents
    °Ç°­°ü¸®¿ä¿ø(ÊÙËíËô), °Ç°­°ü¸®±â±¸.
  • immunosuppressive agents
    ¸é¿ª¾ïÁ¦ÀÎÀÚ(¡­åäð¤ì×í­)
  • 11-beta-hydroxylase
    11-º£Å¸-¼ö»êÈ­È¿¼Ò, 11-º£Å¸-È÷µå·Ï½Ç¶óÁ¦
  • 3-beta-hydroxysteroid dehydrogenase
    3-º£Å¸-È÷µå·Ï½Ã½ºÅ×·ÎÀ̵å Å»¼ö¼ÒÈ¿¼Ò
  • O-Nitrophenyl-beta-galactoside => ONPG
    O-´ÏÆ®·ÎÆä´Ò-º£Å¸-°¥¶ôÅä½Ãµå
  • acetyl-beta-methylcholine
    ¾Æ¼¼Æ¿-º£Å¸-¸ÞÆ¿Äݸ°
  • alpha/beta (¥á/¥â) ratio
    ¥á/¥â ºñ
  • gamma-delta-beta thalassemia
    °¨¸¶-µ¨Å¸-º£Å¸- ÁöÁßÇØ¼ººóÇ÷
  • hypoglycemia, beta cell tumor
    ÀúÇ÷´ç(Áõ), º£Å¸¼¼Æ÷Á¾
  • Ganglionic blocking drugs
    ½Å°æÀýÂ÷´Ü¾àÁ¦(ãêÌèï½ó´Ó¨å·ð¥)
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸°ÈïºÐ¾à, ¾Æµå·¹³¯¸°ÀÚ±ØÁ¦.
  • adrenergic tone
    ¾Æµå·¹³¯¸°¼º ±äÀåµµ
  • adrenergic transmission
    ¾Æµå·¹³¯¸°¼ºÀü´Þ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta-ARK : beta-adrenergic receptor kinase
    º£Å¸-¾Æµå·¹³¯¸°(¼º)¼ö¿ëü ÀλêÈ­È¿¼Ò.
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦.
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°¼º Â÷´ÜÁ¦
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°(¼º) ºÀ¼â<Â÷´Ü>¾à.
  • beta adrenergic receptor
    º£Å¸¾Æµå·¹³¯¸°¼º ¼ö¿ëü(¼ö¿ë±â, °¨¼öü)
  • beta-adrenergic antagonist
    º£Å¸ ¾Æµå·¹³¯¸°¼º ÀúÇØÁ¦
  • beta-adrenergic receptor
    º£Å¸ ¾Æµå·¹³¯¸°¼º ¼ö¿ëü
  • biologic agents
    »ý¹°ÇÐÀûÁ¦Á¦
  • eaton agents
    ÀÌÆ° º´¿øÃ¼
  • health care agents
    °Ç°­°ü¸®¿ä¿ø(ÊÙËíËô), °Ç°­°ü¸®±â±¸.
  • immunosuppressive agents
    ¸é¿ª¾ïÁ¦ÀÎÀÚ(¡­åäð¤ì×í­)
  • law for control of poisonous and powerful agents
    µ¶±Ø¹°Ãëü¹ý(ËÄË»ËŅ̬̃ ËÑ).
  • oral hypoglycemic agents
    °æ±¸´ç´¢º´¾àÁ¦(ÌèÏ¢ÓØèñÜ»å·ð¥).
  • oral hypoglycemic agents
    °æ±¸´ç´¢º´¾àÁ¦(ÌèÏ¢ÓØèñÜ»å·ð¥).
  • proteolytic agents
    ´Ü¹éºÐÇØÁ¦(¡­ÝÂú°ð¥).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Beta cell [Insulin cell]
    º£Å¸¼¼Æ÷ [Àν´¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] º£Å¸¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta adrenergic blocker
    º£Å¸ ¾Æµå·¹³¯¸°ÀÛµ¿(íÂÔÑ) Â÷´ÜÁ¦(ó´Ó¨ð¥)
  • beta adrenergic receptor
    º£Å¸ ¾Æµå·¹³¯¸° ¼ö¿ëü(áôé»ô÷)
  • psychotropic agents
    Á¤½ÅÀÛ¿ë¾à(ïñãêíÂéÄå·)
  • blocking antibody
    Â÷´ÜÇ×ü(ó´Ó¨ù÷ô÷)
  • blocking group
    Â÷´Ü±â(ó´Ó¨Ðñ)
  • adrenergic
    ¾Æµå·¹³¯¸° ÀÛµ¿¼º(íÂÔÑàõ)
  • adrenergic receptor
    ¾Æµå·¹³¯¸°ÀÛµ¿(íÂÔÑ) ¼ö¿ëü(áôé»ô÷)
  • alpha adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³ª¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷)
  • dopamine adrenergic receptor
    "µµÆÄ¹Î ¾Æµå·¹³¯¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷), (ÔÒ) adrenergic receptor"
  • beta
    "º£Å¸, (ÔÒ) ¥â"
  • beta amylase
    º£Å¸ ¾Æ¹Ð·¹À̽º
  • beta bend
    º£Å¸ ±ÁÀ½
  • beta benzyme
    º£Å¸ º¥ÀÚÀÓ
  • beta blocker
    º£Å¸ Â÷´ÜÁ¦(ó´Ó¨ð¥)
  • beta carotene
    º£Å¸ Ä«·ÎÅÙ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta
    º£Å¸
  • beta blocker
    º£Å¸Â÷´ÜÁ¦
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
NMB neuromedin B; neuromuscular blockade; neuromuscular blocking; neuromuscular blocker/blocking [drug, ...
SBF serologic-blocking factor; specific blocking factor; splanchnic blood flow
ADRBK beta-1-adrenergic receptor kinase
ADRBR adrenergic beta-receptor
BAR bariatrics; barometer, barometric; beta-adrenergic receptor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
beta 2AR Beta 2-adrenergic receptors
beta-AR Beta-adrenergic receptor
beta-3-AR Beta-3-adrenergic receptor
beta-ARK beta 2-adrenergic receptor kinase
beta ARK1 Beta-adrenergic receptor kinase 1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • beta-adrenergic blocking agent
    º£Å¸ ¾Æµå·¹³¯¸°¼º Â÷´ÜÁ¦
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸° Â÷´ÜÁ¦
    ¾Æµå·¹³¯¸°¼º ¼ö¿ëü¿¡ ÀÛ¿ëÇÏ¿© ½Å°æ Àü´Þü¿Í ¼ö¿ëü°¡ °áÇÕÇÏÁö ¸øÇÏ°Ô ÇÔÀ¸·Î½á ±³°¨½Å°æ ÈïºÐ È¿°ú¸¦ ºÀ¼âÇÏ´Â ¾à¹°.
  • beta-aminoisobutyric aciduria ¿äÁß¿¡ º£Å¸-¾Æ¹Ì³ë ¾ÆÀ̼ҴлêÀÌ °úµµ·Î ¹è¼³µÇ´Â °Í. ¾ç¼ºÀÇ À¯Àü¼º ´ë»ç¼º ÀÌ»óÀ¸·Î ÀϾ¸ç ±×¸®°í ƯÁ¤ÇÑ Áúȯ¿¡¼­µµ ³ªÅ¸³­´Ù.

    beta-arrestin

    º£Å¸-¾î·¹½ºÆ¾
  • 2-adrenergic agonist
    2-¾Æµå·¹³¯¸° ÀÛ¿ëÁ¦, 2-¾Æµå·¹³¯¸° ÀÛµ¿Á¦
  • adrenergic agonist
    ¾Æµå·¹³¯¸°¼º ÀÛµ¿¾à
    ¾Æµå·¹³¯¸°¼º ¼ö¿ëü¸¦ ÈïºÐ½ÃÅ´À¸·Î½á È¿°ú¸¦ ³ªÅ¸³»´Â ¾à¹°. ´ë°Ô ¾Æ¹Î È­ÇÕ¹°À̹ǷΠ±³°¨½Å°æ À¯»ç ¾Æ¹ÎÀ̶ó°íµµ ÇÑ´Ù.
  • adrenergic fiber
    ¾Æµå·¹³¯¸°¼º ¼¶À¯
  • adrenergic neurotransmitter
    ¾Æµå·¹³¯¸°¼º ½Å°æ Àü´Þ ¹°Áú
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸° ÈïºÐ ¾à, ¾Æµå·¹³¯¸°¼º ÈïºÐ¾à, ¾Æµå·¹³¯¸° ÀÚ±ØÁ¦, ¾Æµå·¹³¯¸°¼º ÀÚ±ØÁ¦
  • adrenergic transmission
    ¾Æµå·¹³¯¸°¼º Àü´Þ
    ³ë¸£¾Æµå·¹³¯¸° ¶Ç´Â ¾Æµå·¹³¯¸°À» Àü´Þ ¹°Áú·Î ÇÏ´Â ÈïºÐ Àü´Þ. ±³°¨½Å°æÀÇ ¹ß´ÜÀ» °ÅÀÇ À̰ÍÀÌ´Ù. ±³°¨ ½Å°æ ¼¶À¯°¡ ÈïºÐÇÏ¸é ¸»´Ü¿¡¼­ ³ë¸£¾Æµå·¹³¯¸° µîÀÌ ¹æÃâµÇ°í À̰ÍÀÌ È¿°ú±âÀÇ ¼ö¿ë±â¿¡ µµ´ÞÇØ ÈïºÐµÈ´Ù. ÈïºÐ
  • adrenergic urticaria
    ¾Æµå·¹³¯¸°¼º µÎµå·¯±â
  • alpha 1-adrenergic blocker
    ¾ËÆÄ 1-¾Æµå·¹³¯¸°¼º Â÷´Ü
  • alpha adrenergic antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸° ±æÇ×Á¦
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸° ¼ö¿ëü
  • ¥â-adrenergic

    ¥â-adrenergic agent (

    ¥â-adrenergic receptor blocking agent (º£Å¸ ¾Æµå·¹³¯¸°¼º ¼ö¿ëü Â÷´ÜÁ¦

  • autonomic blocking agent
    ÀÚÀ² ½Å°æ Â÷´ÜÁ¦
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
beta-adrenergic blocking agent A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable.
Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker.
(05 Mar 2000)
beta-adrenergic receptor blocking agent A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable.
Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker.
(05 Mar 2000)
adrenergic blocking agent A compound that selectively blocks or inhibits responses to sympathetic adrenergic nerve activity (sympatholytic agent) and to epinephrine, norepinephrine, and other adrenergic amines (adrenolytic agent); two distinct classes exist, alpha-and beta-adrenergic receptor blocking agent's.
(05 Mar 2000)
adrenergic neuronal blocking agent A drug that prevents the release of norepinephrine from sympathetic nerve terminals; it does not inhibit the responses of the adrenergic receptors to circulating epinephrine, norepinephrine, and other adrenergic amines.
(05 Mar 2000)
alpha-adrenergic blocking agent An agent that competitively blocks alpha-adrenergic receptors; used in the treatment of hypertension.
Synonym: alpha-blocker.
(05 Mar 2000)
spermatogenesis-blocking agents Chemical substances which inhibit the process of spermatozoa formation at either the first stage, in which spermatogonia develop into spermatocytes and then into spermatids, or the second stage, in which spermatids transform into spermatozoa.
(12 Dec 1998)
neuromuscular blocking agents Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. They can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarising agents) or noncompetitive, depolarising agents (neuromuscular depolarising agents). Both prevent acetylcholine from triggering the muscle contraction and they are used as anaesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.
(12 Dec 1998)
adrenergic agents Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.
(12 Dec 1998)
adrenergic beta-agonists Drugs that selectively bind to and activate beta-adrenergic receptors.
(12 Dec 1998)
adrenergic beta-antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
(12 Dec 1998)
beta-adrenergic receptor kinase <enzyme> Cyclic-AMP protein kinase which specifically phosphorylates the agonist-occupied form of beta-adrenergic receptor
Registry number: EC 2.7.1.-
Synonym: beta-ar kinase, beta-adrenergic receptor kinase 1, g-protein-coupled receptor kinase 2, grk2 (kinase), beta-adrenergic receptor kinase 2, beta-ar kinase 2
(26 Jun 1999)
beta-adrenergic receptors Adrenergic receptor's in effector tissues capable of selective activation and blockade by drugs; conceptually derived from the ability of certain agents, such as propranolol, to block only some adrenergic receptor's and of other agents, such as isoproterenol, to activate only the same adrenergic receptor's. Such receptor's are designated as beta-receptors. Their activation results in physiological responses such as increases in cardiac rate and force of contraction (b1), and relaxation of bronchial and vascular smooth muscle (b2).
(05 Mar 2000)
receptors, adrenergic, beta One of the two major pharmacologically defined classes of adrenergic receptors. The alpha-beta distinction was originally based on the cellular effects of receptor activation but now relies on the relative affinities for characteristic synthetic ligands. Beta adrenergic receptors are further subdivided based on information from endogenous and cloned receptors.
(12 Dec 1998)
receptors, adrenergic, beta-1 A subclass of beta-adrenergic receptors (receptors, adrenergic, beta). Beta-1 adrenergic receptors are equally sensitive to epinephrine and norepinephrine and bind the agonist dobutamine and the antagonist metoprolol with high affinity. They are found in the heart, juxtaglomerular cells, and in the central and peripheral nervous systems.
(12 Dec 1998)
receptors, adrenergic, beta-2 A subclass of beta-adrenergic receptors (receptors, adrenergic, beta). Beta-2 adrenergic receptors are more sensitive to epinephrine than to norepinephrine and have a high affinity for the agonist terbutaline. They are widespread, with clinically important roles in skeletal muscle, liver, and vascular, bronchial, gastrointestinal, and genitourinary smooth muscle.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blocking
    ¿À¸®´ë(Æ´À» ¸Þ¿ì´Â ³ª¹µÁ¶°¢);ºí·ÎÅ·;ÀúÁö Çö»ó(¹Ù¶÷Á÷ÇÏÁö ¾ÊÀº »ó³ä¿¡ ÀÇÇÑ ¿¬»ó Áß´Ü);(¹è¿ìÀÇ)¿¬Ãâ;ºí·ÎÅ·Çϱâ
  • beta
    º£Å¸
  • Phi Beta Kappa
    ÆÄÀÌ.º£Å¸.Ä«ÆÄŬ·´
  • beta
    º£Å¸(±×¸®½º¾î ¾ËÆÄºªÀÇ µÑ° ÀÚ)
  • beta minus
    2·ùÀÇÇÏ;2·ùº¸´Ù Á» ¸øÇÑ
  • beta particle
    º£Å¸ÀÔÀÚ
  • beta rays
    º£Å¸¼±
  • beta rhythm
    º£Å¸¸®µë(¸ÅÃÊ 10ÀÌ»óÀÇ ³úÆÄÀÇ ¹éµ¿)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á